ArticleAlcohol, clinical & experimental research2026
A Role for Glycine Transporter-2 Inhibitors in Regulating Accumbal Dopamine Levels and Voluntary Alcohol Intake in Rats.
Article in Alcohol, clinical & experimental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGlycinergic neurotransmission has been suggested as a tentative pharmacological treatment target for Alcohol Use Disorder (AUD), a devastating brain disease with limited treatment options that involves reduced dopamine (DA) activity in the nucleus Accumbens (nAc) and loss of control of alcohol intake. Glycine receptors (GlyRs) in the nAc, a pivotal part of the brain reward circuitry, are involved in regulating basal and alcohol-induced accumbal DA levels as well as voluntary alcohol intake in rats.
methodsThis study in rats examined if inhibition of the glycine transporter 2 (GlyT-2, SLC6A5), present within glycinergic synapses, alters (1) accumbal DA and glycine content as measured by in vivo microdialysis coupled to HPLC and (2) the alcohol deprivation effect (ADE) in a two-bottle-choice alcohol consumption paradigm. Finally, (3) the presence of GlyT2-expressing fibers and GlyRs in the nAc was examined by immunohistochemistry (IHC).
resultsIn brief, the two partial GlyT2-inhibitors N-Arachidonyl-Glycine (NAGly, 10 mg/kg i.p.) and Opiranserin (20 mg/kg i.p.), but not the full GlyT2-inhibitor Org 25543, slightly elevated accumbal DA levels, while no effects on extrasynaptic glycine levels were observed. The reversible GlyT1-inhibitor Bitopertin (10 mg/kg p.o.) produced a pronounced glycine and DA elevation but combined GlyT1- and GlyT2 inhibition did not yield any statistically significant additive effects. In the alcohol consumption study, NAGly abolished the ADE as compared to placebo treatment. Finally, histology confirmed the presence of GlyT2 and GlyR in the nAc, although with a higher signal for GlyT2 in, for example, septal and basal forebrain regions.
conclusionsOverall, this study indicates that synaptic GlyRs are involved in regulating nAc DA levels and alcohol intake in rats, but probably to a lesser extent than extrasynaptic GlyRs. Further studies that specifically target GlyT2 in, for example, the nAc and septal regions and that utilize refined techniques for measuring synaptic glycine levels are warranted to better characterize the role of glycinergic innervation in the reward circuitry and for regulating alcohol intake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.